| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9955298 | Diabetes Research and Clinical Practice | 2018 | 20 Pages |
Abstract
The effectiveness of APBSCT as a treatment for newly diagnosed DM1 seems to be limited in time. The metabolic control of APBSCT patients is similar to conventionally treated patients. The lower fasting plasma glucose and higher C-peptide achieved with APBSCT seem to not exceed the risks associated with the procedure.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Magdalena Walicka, Alicja Milczarczyk, Emilian Snarski, Krystyna Jedynasty, Kazimierz Halaburda, Tigran Torosian, Elżbieta Urbanowska, MaÅgorzata Król, WiesÅaw Wiktor JÄdrzejczak, Edward Franek,